• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    ICON Announces Appointment of New Chief Financial Officer

    8/14/24 4:15:00 PM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $ICLR alert in real time by email

    ICON plc (NASDAQ:ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced the appointment of Nigel Clerkin as its new Chief Financial Officer (CFO).

    Nigel brings extensive experience and capability to the role of CFO. He commenced his career with KPMG, before joining Elan Corporation where he held a number of roles of increasing responsibility over a fifteen-year career, culminating in the role of group CFO in 2011, which he held until 2014. Nigel then moved to be CFO at ConvaTec, a global medical and technologies company, before becoming UDG Healthcare's CFO in 2018. During his tenure with UDG, he led substantial change and improvement programmes and oversaw strong financial growth across multiple business lines. Most recently, Nigel was CFO at LetsGetChecked, a global provider of at-home healthcare services.

    Nigel has a long tenure and a strong track record of success as CFO in a number of large organisations in the life sciences and healthcare services industry. He has successfully led and supported the financial growth of a number of organisations and has a strong background as a CFO of a public company with significant experience in M&A as well as financial processes and systems enhancement.

    Nigel holds a Bachelor of Science (Accounting) degree and a Master of Accounting degree from Queen's University Belfast and is also a qualified chartered accountant and a fellow of Chartered Accountants Ireland.

    Nigel will be based in ICON's Dublin office and will join ICON early in quarter four this year.

    "I am pleased to announce Nigel's appointment as ICON's next CFO," said Steve Cutler, ICON's CEO. "His vast experience as a CFO across a number of life science and healthcare service organisations will bring valuable experience, insights and new perspectives to the role. I look forward to working with Nigel in the years ahead as ICON continues to grow and become the healthcare intelligence partner of choice for all of our customers. Finally, I would also like to thank our outgoing CFO, Brendan Brennan, for his significant contribution to ICON over the past 18 years and wish him further success in the future."

    "It is a privilege to have been selected to be ICON's next CFO," said Nigel Clerkin. "ICON is a company I have long admired and respected and I have been continuously impressed with the company's performance and continuing growth as a market leader within the CRO industry. I look forward to working with the ICON Executive team and working closely with the strong talent across the organisation particularly within the finance team, to continue ICON's growth and success into the future."

    About ICON plc

    ICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 41,100 employees in 97 locations in 55 countries as at June 30, 2024. For further information about ICON, visit: www.iconplc.com.

    This press release contains forward-looking statements, including statements about our financial guidance. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as other economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, F-4, S-8, F-3 and certain other reports, which are available on the SEC's website at http://www.sec.gov.

    ICON/ICLR-F

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240814475660/en/

    Get the next $ICLR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ICLR

    DatePrice TargetRatingAnalyst
    4/29/2025$150.00Overweight → Neutral
    Analyst
    4/14/2025$157.00Buy → Hold
    TD Cowen
    4/10/2025$165.00Overweight → Equal Weight
    Barclays
    3/21/2025$250.00 → $200.00Buy → Neutral
    Goldman
    1/7/2025$263.00Outperform
    RBC Capital Mkts
    10/24/2024$340.00Outperform → Neutral
    Robert W. Baird
    10/14/2024Neutral
    Redburn Atlantic
    9/18/2024$379.00Outperform
    Leerink Partners
    More analyst ratings

    $ICLR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ICON plc downgraded by Analyst with a new price target

      Analyst downgraded ICON plc from Overweight to Neutral and set a new price target of $150.00

      4/29/25 8:06:12 AM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • ICON plc downgraded by TD Cowen with a new price target

      TD Cowen downgraded ICON plc from Buy to Hold and set a new price target of $157.00

      4/14/25 8:13:29 AM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • ICON plc downgraded by Barclays with a new price target

      Barclays downgraded ICON plc from Overweight to Equal Weight and set a new price target of $165.00

      4/10/25 8:49:19 AM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ICLR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ICON plc to Present at the William Blair 45th Annual Growth Stock Conference

      ICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the William Blair 45th Annual Growth Stock Conference on Wednesday, June 4, 2025 at 10.40 am CT. Any changes to this event and links to the live webcast (where available) will be posted on the Investor section of our website under "Events". About ICON plc ICON plc is a world-leading clinical research organisation powered by healthcare intelligence. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public he

      5/27/25 8:30:00 AM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • ICON releases its ICON Cares 2024 Report

      ICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today releases its ICON Cares 2024 Report. The report outlines how the company is delivering on its environmental, social and governance (ESG) goals, as delivered through its ICON Cares program. In recognition of its efforts in 2024, ICON received a score of 72/100 from EcoVadis, a leading provider of business sustainability ratings, an increase of two points on the previous score, earning ICON a silver medal. ICON also achieved a B- score on its CDP Climate Change response. Most recently, ICON has been named by TIME magazine as one the World's Best Companies in Sustainable Growth 202

      5/19/25 4:15:00 PM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Global ICON survey shows need for more efficient obesity clinical trial design to realise full potential of next-gen multi-indication therapies

      ICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of 155 biotech and pharma professionals from across the US and Europe focusing on multi-indication cardiometabolic R&D for therapies targeting obesity and its comorbidities. Multi-indication studies are clinical trials that test how a treatment works for more than one condition or disease. As researchers uncover the potential of particular drug classes across interconnected diseases, the commercial opportunities have increased the appetite for additional research that targets multiple indications. The findings indicate that most sponsors (83% o

      5/7/25 7:27:00 AM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ICLR
    SEC Filings

    See more
    • SEC Form 6-K filed by ICON plc

      6-K - ICON PLC (0001060955) (Filer)

      6/18/25 5:14:28 PM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 6-K filed by ICON plc

      6-K - ICON PLC (0001060955) (Filer)

      6/11/25 4:18:21 PM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 6-K filed by ICON plc

      6-K - ICON PLC (0001060955) (Filer)

      5/27/25 8:34:09 AM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care